|
시장보고서
상품코드
2051148
동반 진단(CDx) 시장 : 기술별, 용도별, 최종사용자별, 지역별Companion Diagnostics Market, By Technology Type, By Application, By End User, By Region |
||||||
동반 진단(CDx) 시장은 2026년에 98억 6,000만 달러로 추정되며, 2033년까지 224억 8,000만 달러에 이를 전망입니다. 또한 2026-2033년 CAGR 12.5%를 기록할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 98억 6,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 12.50% | 2033년 시장 규모 예측 : | 224억 8,000만 달러 |
동반 진단(CDx)은 환자의 특정 바이오마커나 유전자를 검출하여 특정 치료법에 가장 적합한 환자를 식별하는 데 도움이 되는 의료기기입니다. 이러한 진단법은 의사가 암 및 기타 질병에 대한 적절한 표적 치료법을 선택할 수 있도록 지원함으로써 맞춤형 의료에서 중요한 역할을 하고 있습니다. 동반진단검사는 특정 약물에 대한 환자의 반응에 관여하는 단백질, 유전자, 염색체 등의 바이오마커의 발현을 평가하는 검사입니다. 이러한 바이오마커의 발현 수준을 분석하면 특정 약물이 특정 환자 또는 특정 질환을 가진 환자군에게 안전하고 효과적인지 여부를 파악하는 데 도움이 됩니다. 이를 통해 적절한 환자에게만 전문적인 치료가 이루어지도록 보장하여 치료 결과를 향상시킬 수 있습니다.
시장 역학
세계 동반진단 시장은 맞춤의료에 대한 수요 증가, 분자진단의 성장, 새로운 표적치료제 및 동반진단의 승인 증가, 기술 발전, 암 및 기타 만성질환의 유병률 및 유병률 증가에 힘입어 성장세를 보이고 있습니다. 그러나 이러한 분자진단 검사의 개발 및 상용화에 따른 높은 가격 압박과 규제상의 번거로움은 시장 성장을 제한하는 요인으로 작용할 수 있습니다. 이 시장의 주요 기회 요인으로는 면역요법용 바이오마커 및 동반진단법 개발, 비종양성 질환에 대한 적용 확대, 체외진단(IVD) 기업과 제약사 간의 정밀의료 제휴, 신흥 시장에서의 동반진단법 개발에 대한 관심 증가, 바이오마커 검출을 위한 차세대 염기서열분석(NGS) 등 첨단 기술의 채택 등이 있습니다. 위한 차세대 염기서열분석(NGS) 등 첨단 기술 도입 등을 들 수 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개변수(기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 기반으로 세계 동반진단 시장의 주요 기업 프로파일을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 동반진단 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 동반진단 시장을 분석하는 데 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 동반 진단(CDx) 시장 : 기술 유형별, 2021년-2033년
제5장 세계의 동반 진단(CDx) 시장 : 용도별, 2021년-2033년
제6장 세계의 동반 진단(CDx) 시장 : 최종사용자별, 2021년-2033년
제7장 세계의 동반 진단(CDx) 시장 : 지역별, 2021년-2033년
제8장 경쟁 구도
제9장 섹션
LSH 26.06.17Companion Diagnostics Market is estimated to be valued at USD 9.86 Bn in 2026 and is expected to reach USD 22.48 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9.86 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.50% | 2033 Value Projection: | USD 22.48 Bn |
Companion diagnostics are medical devices that are used to detect specific biomarkers or genes in patients that help determine which patients are most suitable candidates for a particular therapy. These diagnostics play an important role in personalized healthcare by helping physicians select appropriate targeted treatment options for cancer and other diseases. Companion diagnostics tests evaluate the expression of biomarkers, such as proteins, genes or chromosomes that plays a role in a patient's response to a specific drug. By analyzing the expression levels of such biomarkers, these tests help to identify whether a particular drug would be safe and effective for a specific patient or set of patients with a given disease. This enables better therapeutic outcomes by ensuring only suitable patients receive specialized treatments.
Market Dynamics
Global companion diagnostics market is driven by rising demand for personalized medicine, growth in molecular diagnostics, increasing approvals of new targeted therapies & companion diagnostics, technological advancements, and growing incidence and prevalence of cancer, and other chronic diseases. However, the market growth can be restricted by high pricing pressure and regulatory hassles that are involved in developing and commercializing these molecular diagnostic tests. Key opportunities in this market include developing biomarkers and companion diagnostics for immunotherapies, expanding applications in non-oncology diseases, precision medicine collaborations between In vitro diagnostics (IVD) companies and drug makers, growing focus on companion diagnostic development in emerging markets, and adoption of advanced technologies like Next-generation sequencing (NGS) for biomarker detection.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global companion diagnostics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V, Abbott Laboratories, Inc., Almac Group, Danaher Corporation, Illumina, Inc., bioMerieux SA, Myriad Genetics, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Abnova Corporation, Guardant Health, Inc., Icon Plc., and Biogenex Laboratories, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global companion diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global companion diagnostics market
Market Segmentation
- By Technology Type (Revenue, USD Bn, 2021 - 2033)
- Real Time-Polymerase Chain Reactions (PCR)
- Gene Sequencing
- Fluorescence in situ Hybridization
- Others
- By Application (Revenue, USD Bn, 2021 - 2033)
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Diseases
- Others
- By End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Research Laboratories
- Biopharmaceutical companies
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hoffmann-La Roche AG
- Agilent Technologies, Inc
- QIAGEN N.V
- Abbott Laboratories, Inc.
- Almac Group
- Danaher Corporation
- Illumina, Inc.
- bioMerieux SA
- Myriad Genetics, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Abnova Corporation
- Guardant Health, Inc.
- Icon Plc.,
- Biogenex Laboratories, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Technology Type
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing number of cancer patients
- Complexity of Integration
- Emerging markets
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions and Collaborations
4. Global Companion Diagnostics Market, By Technology Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Real Time-Polymerase Chain Reactions (PCR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gene Sequencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Fluorescence in situ Hybridization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Companion Diagnostics Market, By Application, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Neurological Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Companion Diagnostics Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Research Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Biopharmaceutical companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Companion Diagnostics Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Company Profiles
- F.Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent Technologies, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- QIAGEN N.V
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abbott Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Almac Group
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Illumina, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- bioMerieux SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Myriad Genetics, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sysmex Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Thermo Fisher Scientific Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abnova Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Guardant Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Icon Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biogenex Laboratories, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F.Hoffmann-La Roche AG
- Analysts' Views
9. Section
- References
- Research Methodology
- About us
